Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C
Record ID 32011000931
English
Authors' objectives:
The purpose of the ERG report was to comment n the validity of the manufacturer’s submission on the technology of interest. The scope for this submission and hence the scope for the ERG report is shown in Table 1.
Authors' recommendations:
The ERG was generally in agreement with the submitting manufacturer concerning its estimates of effectiveness.There was greater concern about the estimates of cost-effectiveness. The ERG judged that if the potential errors were corrected, the ICERs offered by the submitting manufacturer overstate the cost-effectiveness of everolimus for the second-line treatment of metastatic RCC (this ICER would be higher).
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hta.ac.uk/project/2155.asp
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Cost-Benefit Analysis
- England
- Randomized Controlled Trials as Topic
- Wales
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Sirolimus
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.